Zydus Lifesciences Ltd

Zydus Lifesciences Ltd

ZYDUSLIFE

 882.42
- 29.23
3.21%
Healthcare
 0.00
(%)1D
Updated: 10 Feb 2026, 03:31:40 pm IST
Stock Score
Open Price
 911.89
Prev. Close
 911.65
 879.48
Day Low
 911.89
Day High

 793.42
52 Week Low
 1,044.61
52 Week High

Quick Bite

Price To Earnings Ratio

17.98

Sector PE

36.12

PB Ratio

3.71

Sector PB

5.02

EPS

49.09

Dividend Yield

1.24

Today's Volume

2.273 M

5 Day Avg. Volume

1.151 M

PEG Ratio

1.04

Market Cap.

₹ 89,370.00 Cr.

News & Events

About Zydus Lifesciences Ltd

Zydus Lifesciences Limited is an India-based life-sciences company with positions across pharmaceuticals and consumer wellness, supported by a MedTech franchise and a global footprint across United States, India and other international markets. Its pharmaceutical business includes integrated pharmaceutical operations with business encompassing the entire value chain in research, development, production, marketing and distribution of pharmaceutical products. Its product portfolio includes active pharmaceutical ingredients, human formulations, and animal health and veterinary. Its consumer products business includes development, production, marketing and distribution of differentiated health and wellness products. It provides biologicals manufacturing sites offering contract development and manufacturing organization services to biopharmaceutical companies globally. Its focused therapy areas include cardiology, anti-diabetes, super specialty areas of oncology and nephrology, and others.

Zydus Lifesciences Ltd Share Price

Zydus Lifesciences Ltd. is an Indian life sciences company. The Company is engaged in the research and development, manufacturing, marketing and sale of human medicines, such as generic medicines and specialty products, including biosimilars and vaccines; active pharmaceutical ingredients (API); animal health products and consumer protection products. Its products include Bilypsa (saroglitisar), Oxemia (desidustat), Ujvira (biologically similar to Kadcyla), and Exemptia. It offers Bilypsa for the treatment of non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH). Desidustat is an oral, small molecule, hypoxia-inducible factor-prolyl-hydroxylase (HIF-PH) inhibitor used to treat anemia in patients with chronic kidney disease (CKD). He is also developing an oral ZYIL1 small molecule to selectively suppress inflammation caused by the NLRP3 inflammasome. Its ZyCoV-D is a plasmid deoxyribonucleic acid (DNA) vaccine against COVID-19.

Zydus Lifesciences Ltd FAQs

How to Buy Zydus Lifesciences Ltd Share?

up
To purchase Zydus Lifesciences Ltd shares, you can open a Demat & Trading account through a broker or financial institution. Once your account is set up and funded, search for Zydus Lifesciences Ltd (ticker symbol: ZYDUSLIFE) on the trading platform provided by your broker and purchase the shares.

What's Zydus Lifesciences Ltd share price today?

up
The stock price of Zydus Lifesciences Ltd as of 10 Feb 2026 is ₹882.42

What is the Market Cap of Zydus Lifesciences Ltd?

up
Market capitalisation represents the total market value of a company's outstanding shares. As of 10 Feb 2026, Zydus Lifesciences Ltd (ticker symbol: ZYDUSLIFE) has a market capitalisation of approximately ₹8,93,70,00,00,000.00

What is the PE and PB ratio of Zydus Lifesciences Ltd?

up
Zydus Lifesciences Ltd Ltd's price-to-book ratio as of 10 Feb 2026 is 3.71, reflecting the market's valuation compared to its asset value. As of 10 Feb 2026, the trailing twelve months P/E (price-to-earnings) ratio is 17.98, indicating the market values the company at around ₹17.98 for every ₹1 of earnings

What is the 52 Week High and Low of Zydus Lifesciences Ltd Share?

up
Zydus Lifesciences Ltd Ltd (ZYDUSLIFE) hit its 52-week high at ₹1,044.61, and its 52-week low at ₹793.42.
Begin your investment journey today
Login/Register
Start Now